Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27480558 | 0.80 | NPSR1 (0.49) | NPSR1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1043396 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1LMNACA12CA9 | |
| SCHEMBL11313543 | 0.79 | CA1 (0.35) | SMN1; SMN2ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL1570351 | 0.77 | NPSR1 (0.47) | NPSR1SMN1; SMN2ALDH1A1GFERKMT2A | |
| SCHEMBL945862 | 0.77 | SMN1; SMN2 (0.61) | NPSR1SMN1; SMN2ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL4315277 | 0.76 | LMNA (0.31) | SMN1; SMN2LMNAKDM4E | |
| SCHEMBL28435387 | 0.76 | MEN1 (0.38) | SMN1; SMN2ALDH1A1CYP1A2GFERKMT2A | |
| SCHEMBL1419231 | 0.75 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1CYP2C9KMT2ALMNA | |
| SCHEMBL3107054 | 0.75 | MAPT (0.54) | SMN1; SMN2ALDH1A1CYP2C9KMT2AMEN1 | |
| SCHEMBL11512348 | 0.75 | SMN1; SMN2 (0.59) | NPSR1SMN1; SMN2ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668182-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | claimed |
| EP-2668183-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | claimed |
| EP-2668183-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC Discovery GmbH (DE) | 2013-12-04 | — | — | EP | claimed |
| US-8354436-B2 | IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation | 4SC DISCOVERY GMBH (DE) | 2013-01-15 | — | — | US | claimed |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | claimed |
| US-20120196862-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | claimed |
| WO-2012101263-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | WO | claimed |
| EP-2668182-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2668183-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| CN-103476771-B | IL17 and the IFN-γ being used for the treatment of autoimmune inflammation suppresses | 4SC DISCOVERY GMBH (DE) | 2015-12-23 | — | — | CN | disclosed |
| CN-103459385-B | IL17 and the IFN-γ being used for the treatment of autoimmune inflammation suppresses | 4SC DISCOVERY GMBH (DE) | 2015-08-05 | — | — | CN | disclosed |
| EP-2668183-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC Discovery GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| EP-2668182-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC Discovery GmbH (DE) | 2013-12-04 | — | — | EP | disclosed |
| EP-2042502-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-04-01 | — | — | EP | disclosed |
| EP-1544199-B1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2008-07-03 | — | — | US | disclosed |
| US-7211572-B2 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-05-01 | — | — | US | disclosed |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1544199-A1 | NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054645-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | NPSR1 3539/4885SMN1; SMN2 2501/4885ALDH1A1 2068/4885 |
| US-20120196862-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | IFNG, IL17A, IL2 | NPSR1 2038/4885SMN1; SMN2 3903/4885ALDH1A1 1434/4885 |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | IFNG, IL17A, IL2 | NPSR1 2038/4885SMN1; SMN2 3903/4885ALDH1A1 1434/4885 |
| US-20060052361-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | NNMT, PNP, DNTT | NPSR1 3539/4885SMN1; SMN2 2501/4885ALDH1A1 2068/4885 |
| US-20080161311-A1 | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor | DNTT, PNP, NNMT | NPSR1 2940/4885SMN1; SMN2 2251/4885ALDH1A1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.